Lexicon Pharmaceuticals (LXRX) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Lexicon Pharmaceuticals (LXRX) over the past year, gaining 218.9% versus a gain of 14.2%. Lexicon Pharmaceuticals is the larger company by market cap ($681.2 million vs $666.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXRX | NVCT |
|---|---|---|
| Share price | $1.53 | $19.39 |
| Market cap | $681.21M | $666.80M |
| 1-day change | -8.38% | -2.27% |
| YTD return | +33.04% | +156.82% |
| 1-year return | +14.18% | +218.91% |
| 5-year return | -67.72% | — |
| EPS (TTM) | $-0.15 | $-2.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $49.80M | — |
| Revenue growth (YoY) | +60.24% | — |
| Net income (latest FY) | $-50.34M | $-26.44M |
| Gross margin | 99.45% | — |
| Operating margin | -98.21% | — |
| Net margin | -101.08% | — |
| 52-week high | $2.68 | $29.28 |
| 52-week low | $1.10 | $5.77 |
| Distance from 52-week high | -42.91% | -33.77% |
| Analyst consensus | buy | none |
| Avg. price target upside | +195.42% | +82.57% |
| Average volume | 2.56M | 206.37K |
| Shares outstanding | 445.23M | 34.39M |
| Employees | 81 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed LXRX by 204.7 percentage points over the past year.
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
LXRX vs NVCT FAQ
Which is bigger, Lexicon Pharmaceuticals or Nuvectis Pharma?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $681.21M compared with $666.80M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, LXRX or NVCT?
NVCT returned +218.91% over the past 12 months, compared with +14.18% for LXRX (price return, excluding dividends). Past performance does not predict future results.
Are Lexicon Pharmaceuticals and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.